Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of DS-8201a in subjects with advanced solid malignant tumors
jRCT2080222926Phase 1Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jul 2015
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of trastuzumab deruxtecan in breast cancer, gastric cancer (GC), gastroesophageal junction adenocarcinoma and 2 more, sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Safety and tolerability of trastuzumab deruxtecan and Determination of recommended phase 2 dose (RP2D). Started Jul 2015; status: completed.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancergastric cancer (GC)gastroesophageal junction adenocarcinomaNon-hematologic malignancyHER2-mutant cancer (HER2m)
Beyond the preview
Go deeper on jRCT2080222926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222926.